Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers of the Novel Self-Administered Intranasal CG- SpikeDown Antiviral Drug
Clinical trial NCT05234320 · UNKNOWN
Trial details
- NCT number
- NCT05234320
- Sponsor
- Caregen Co. Ltd.
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-01
- Primary completion
- 2023-01-01
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.